The activity of CYP450 enzymes can significantly impact the efficacy and safety of cancer therapies. These enzymes metabolize many anticancer drugs, influencing their plasma levels and, consequently, their therapeutic and toxic effects. For instance, CYP3A4 metabolizes approximately 50% of all marketed drugs, including many used in chemotherapy such as paclitaxel and doxorubicin.
